College Stock: Penny Stock News

While the AIDS Vaccine Conference this week in Paris has further highlighted the growing HIV/AIDS epidemic and the need for an effective treatment and vaccine, there’s certainly no shortage of information for The Dean of Penny Stocks to relay to the CollegeStock Community. Upon further review of the Thailand AIDS vaccine trial, the world now knows the truth about its modest results but The Dean believes its findings, although statistically insignificant, will be analyzed and dissected for months and possibly years to come.

The Dean believes that the world has recognized the absolute need for an effective HIV/AIDS treatment and vaccine because huge numbers do not lie.

Time and time again, the fact that more than 33 million in the world are infected and 7,400 more become infected with HIV everyday is daunting for some. That’s why The Dean sees the potential for companies like Viral Genetics (OTC: VRAL) who are working to combat this disease that has claimed the lives of 25 million people to date. With 2.7 million new cases every year, both the number of people infected and lives claimed by HIV could increase dramatically over the next decade.

Dr. Luc Montagnier, was awarded the Nobel Prize in 2008 for the discovery of the HIV virus. As The Dean’s students may or may not know, Dr. Montagnier is also an advisory board member at $VRAL and believes trial vaccines should be tested in populations that are most at risk. From the information The Dean has taught the CollegeStock Community, we all know a successful vaccine could benefit countries on the African and Asian continents the most.

Finding a cure for HIV/AIDS is critical because it will allow life to continue for millions and prevent millions, if not billions, more from becoming infected. But an article from South African newspaper The Southern Times revealed another interesting motive for finding an effective treatment for the deadly disease: national security.

The Southern Times references a 1998 UNAIDS report that suggests military personnel are believed to be 200% to 500% more likely to contract HIV. The article also discusses that “HIV is severely affecting the armed forces of many African countries” and, as a result, the countries themselves are being weakened and less secure.

The Dean thinks this information is scary because it’s not limited to just African countries with high concentrations of HIV populations. In fact, and unnamed country in Eastern Europe rejected 9,000 potential recruits because they tested positive for HIV. Since 2003, that same country has made it a policy to reject individuals who are HIV positive from military service.

The Dean believes this is significant for nations around the world in times of war and peace, as many countries with high HIV prevalence could find it difficult to “send their soldiers for peacekeeping” efforts in other countries. Also, these countries are subjected to the costs incurred because of greater needs for antiretrovirals and other treatments. In many developing countries, poverty and famine cause enough devestation and funds for medical care are not necessarily a priority.

This is why The Dean feels many groups, such as UNICEF, UNAIDS and other government organizations, push for treatment and vaccine trials in countries like South Africa.

As the recent Thailand trials and their debunked results have proven, the fight against HIV/AIDS is uphill and continuous. Nevertheless, The Dean of Penny Stocks thinks $VRAL could reduce the threat of HIV/AIDS around the world by treating the disease where it’s most heavily concentrated.